RAdium-223 and SABR Versus SABR for Oligometastatic Prostate Cancers (RAVENS)
A Phase II Randomized Trial of RAdium-223 and SABR Versus SABR for oligomEtastatic Prostate caNcerS (RAVENS)
Sponsor: Bayer
This PHASE2 trial investigates Prostate Cancer and is currently completed. Bayer leads this study, which shows 12 recorded versions since 2019 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
12 versions recorded-
Jan 2026 — Present [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Dec 2024 — Jan 2026 [monthly]
Active Not Recruiting PHASE2
-
Sep 2024 — Dec 2024 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Jun 2023 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
▶ Show 7 earlier versions
-
Apr 2023 — Jun 2023 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jun 2022 — Apr 2023 [monthly]
Recruiting PHASE2
-
Jun 2021 — Jun 2022 [monthly]
Recruiting PHASE2
-
Jan 2021 — Jun 2021 [monthly]
Recruiting PHASE2
-
Jun 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Oct 2019 — Jun 2020 [monthly]
Recruiting PHASE2
-
Aug 2019 — Oct 2019 [monthly]
Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Bayer
- Congressionally Directed Medical Research Programs
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
For direct contact, visit the study record on ClinicalTrials.gov .